Antibiotic resistance is rising in veterinary medicine. Analyze the FDA NARMS dataset of 318,168 canine records to understand MRSP, resistant E. coli, and key clinical decisions.

If your veterinarian recently handed you a culture and susceptibility report for your dog with a persistent skin, ear, or urinary tract infection, you may have been confronted with a list of antibiotics that are labeled "Resistant." Seeing terms like "Methicillin-Resistant Staphylococcus pseudintermedius" (MRSP) or finding that a common bacterium like Escherichia coli is resistant to multiple first-line drugs can be alarming for any pet owner and challenging for any veterinary clinical team.

In veterinary medicine, we are witnessing a significant shift in how we manage bacterial infections. The era of choosing a broad-spectrum antibiotic by "best guess" (empiric therapy) without testing is rapidly closing. To understand the true scale of this challenge, we must look beyond clinical anecdotes and examine systematic national surveillance data.

This article reviews the current state of antibiotic resistance in dogs. We analyze the FDA's National Antimicrobial Resistance Monitoring System (NARMS) animal pathogen dataset—incorporating 318,168 canine isolate-drug test rows from 2017 to 2021—to quantify exactly how common resistance is to our most vital veterinary drugs. We discuss the clinical distinction between MRSP and human MRSA, outline what a resistant culture result actually means for your dog's treatment, assess the zoonotic risks to humans and other pets, and establish clear decision pathways for when to seek specialized dermatological referral.

The short answer, first

Antibiotic resistance is common and measurable in dogs, but it does not mean an infection is untreatable. In the FDA's NARMS companion-animal surveillance database spanning 2017 to 2021, approximately 34.28% of canine Staphylococcus pseudintermedius isolates were oxacillin-resistant (the established laboratory marker for methicillin resistance and MRSP). Furthermore, resistance to first-line fluoroquinolones (such as enrofloxacin) reached 40.00% in S. pseudintermedius isolates, while 34.02% of canine Escherichia coli isolates showed resistance to ampicillin.

These numbers indicate that standard empiric therapy (prescribing antibiotics without a culture) is increasingly likely to fail for recurrent or deep infections. A "Resistant" result on a culture report does not mean there are no options left; rather, it indicates that treatment must be precisely tailored using culture and susceptibility (C&S) testing to target the specific organism.

For a summary of the most common veterinary antibiotics and their general safety profiles, see our guide on antibiotic adverse-event data. To learn how veterinary practices can combat this trend through operational protocols, read our playbook on building a clinic antimicrobial stewardship program.

What is antimicrobial resistance (AMR) in dogs?

Antimicrobial resistance occurs when bacteria evolve mechanisms to protect themselves from the effects of antibiotics. These mechanisms can include producing enzymes that destroy the drug (such as beta-lactamases), altering the bacterial cell wall to prevent the drug from binding, or active efflux pumps that eject the antibiotic from the cell.

In small-animal veterinary medicine, two pathogens represent the primary fronts of the resistance battle:

1. Methicillin-Resistant Staphylococcus pseudintermedius (MRSP)

Staphylococcus pseudintermedius is a normal inhabitant of the skin and mucous membranes of healthy dogs. However, it is also the primary opportunistic pathogen responsible for canine pyoderma (skin infections) and otitis externa (ear infections).

When S. pseudintermedius acquires the mecA gene, it alters its penicillin-binding proteins, rendering it resistant to virtually all beta-lactam antibiotics. This includes penicillins (ampicillin, amoxicillin), potentiated penicillins (amoxicillin-clavulanate or Clavamox), and cephalosporins (cephalexin, cefpodoxime or Simplicef, and convenia or cefovecin). In veterinary medicine, we call this strain MRSP.

The clinical difference between MRSP and MRSA

It is critical to distinguish between MRSP and MRSA (Methicillin-Resistant Staphylococcus aureus):

MRSA is primarily a human pathogen. While dogs can contract MRSA, they almost always acquire it from a human household member. Dogs generally clear MRSA infections quickly because S. aureus is not adapted to live on canine skin.
MRSP is adapted specifically to dogs. It can persist on canine skin and in the household environment for months. While it can transiently colonize humans who handle infected dogs, it rarely causes active infection in healthy people. However, for dogs, MRSP is a highly persistent, recurring cause of severe dermatitis and wound infections.

In 2021, the European Food Safety Authority (EFSA) officially designated S. pseudintermedius as one of the three most relevant resistant bacteria threatening the health of dogs and cats in the European Union, highlighting its status as a major global veterinary priority.

2. Resistant Escherichia coli

Escherichia coli is a Gram-negative bacterium that resides in the gastrointestinal tracts of dogs. While normally harmless in the gut, it is the primary pathogen responsible for canine urinary tract infections (UTIs), pyometra, and soft-tissue infections.

Unlike staphylococcus, which is Gram-positive, E. coli has an outer membrane that naturally limits the penetration of some antibiotics. When E. coli acquires plasmid-mediated resistance genes—such as those encoding Extended-Spectrum Beta-Lactamases (ESBL)—it becomes resistant to third-generation cephalosporins and often carries co-resistance to fluoroquinolones, tetracyclines, and sulfonamides, leaving very few oral treatment options.

The FDA NARMS dataset: Surveillance vs. clinic prevalence

To quantify the true rates of resistance in US dogs, we analyzed the FDA's National Antimicrobial Resistance Monitoring System (NARMS) animal pathogen dataset. This database tracks isolates submitted by the National Animal Health Laboratory Network (NAHLN), which comprises state and university diagnostic laboratories across the country.

Our analysis of the latest 2017–2021 dataset includes 318,168 individual dog isolate-drug test rows.

Understanding the surveillance caveat

When interpreting this data, clinical teams and pet owners must understand a key epidemiological distinction: Surveillance data is not healthy-dog clinic prevalence. The isolates submitted to NAHLN diagnostic laboratories come from sick dogs whose veterinarians requested a culture and susceptibility test. Because veterinarians are far more likely to request a culture for a patient that has already failed one or more empiric courses of antibiotics, these isolates are naturally pre-selected for higher resistance.

Therefore, these percentages represent the resistance rates in clinical cases where a culture was deemed necessary, not the background rate of resistance in every healthy dog walking into a clinic. They represent the "worst-case" scenario that a clinician must navigate when an empiric treatment fails.

Staphylococcus pseudintermedius: Drug-by-drug resistance rates

Across 157,947 rows of canine S. pseudintermedius isolate-drug testing in the NARMS database, the overall resistance rate was 27.2%. This means that more than a quarter of all drug-susceptibility tests performed on canine staph returned a "Resistant" result.

The table below breaks down the exact resistance rates for the primary antibiotics utilized in veterinary dermatology and general practice:

Table 1: Antibiotic resistance rates in canine Staphylococcus pseudintermedius (FDA NARMS, 2017–2021)

Antibiotic	Drug Class / Generation	Tests (N)	Resistant Count	Resistance %	Clinical Relevance
Oxacillin	Penicillin (MRSP Marker)	7,362	2,524	34.28%	Standard laboratory proxy for methicillin/beta-lactam resistance.
Clindamycin	Lincosamide	7,406	2,238	30.22%	Frequently used for superficial pyoderma; high rate of inducible resistance.
Enrofloxacin	Fluoroquinolone (2nd Gen)	7,377	2,951	40.00%	Broad-spectrum; resistance indicates severe fluoroquinolone failure.
Cefpodoxime	Cephalosporin (3rd Gen)	7,421	1,508	20.32%	Labeled for canine skin infections (Simplicef); once-daily oral tablet.
Gentamicin	Aminoglycoside	7,457	1,253	16.80%	Primarily topical (ear drops/sprays); systemic use limited by nephrotoxicity.
Erythromycin	Macrolide	7,415	2,291	30.90%	Macrolide resistance closely mirrors clindamycin resistance patterns.
Rifampin	Rifamycins	7,254	81	1.12%	Highly active but must never be used as monotherapy due to rapid mutation.
Tetracycline	Tetracycline	6,878	3,182	46.26%	High baseline resistance; acts as a proxy for doxycycline susceptibility.

Source: Computed by VetMedGuide from FDA NARMS companion-animal pathogen surveillance — interpretable susceptibility results, 2017–2021. Resistance % = Resistant ÷ (Susceptible + Intermediate + Resistant).

Key takeaways from the S. pseudintermedius data

1. The methicillin resistance baseline (Oxacillin at 34.28%)

Oxacillin is the laboratory agent used to detect methicillin resistance. A resistance rate of 34.28% means that more than one-third of the staph isolates cultured from dogs undergoing diagnostic workups are MRSP. For these dogs, standard oral antibiotics like cephalexin, cefpodoxime (Simplicef), and Clavamox are completely ineffective.

To explore treatment alternatives for cephalosporin-sensitive cases, see our clinical review on cefpodoxime (Simplicef) for dogs.

2. The fluoroquinolone failure rate (Enrofloxacin at 40.00%)

Fluoroquinolones like enrofloxacin (Baytril) and marbofloxacin (Zenquin) are often regarded as "heavy hitter" drugs, reserved for deep infections or Gram-negative coverage. However, the NARMS data reveals that 40.00% of S. pseudintermedius isolates are resistant to enrofloxacin.

This high rate demonstrates that using fluoroquinolones empirically is no longer clinically defensible. If a staph infection is resistant to cephalosporins, it is highly likely to be resistant to fluoroquinolones as well.

3. The role of tetracyclines and doxycycline (Tetracycline at 46.26%)

In laboratory testing, tetracycline susceptibility is used to predict doxycycline efficacy. With 46.26% resistance, nearly half of the cultured staph isolates will fail doxycycline therapy. Doxycycline is often reached for as a cheap oral option, but these figures highlight its poor utility in chronic or recurrent pyodermas without culture support.

4. The Rifampin rescue (1.12% resistance)

Rifampin remains highly effective, with only 1.12% resistance in US dog isolates. However, rifampin has a significant clinical catch: bacteria can develop resistance to it via a single-point mutation. If rifampin is prescribed alone, the bacteria can become resistant mid-treatment. Therefore, rifampin must always be paired with another susceptible antibiotic (such as clindamycin or cephalosporin, if susceptibility exists) and is strictly reserved for confirmed multidrug-resistant cases under close veterinary supervision.

Escherichia coli: Drug-by-drug resistance rates

Gram-negative infections present a distinct therapeutic challenge. Across 134,510 interpretable canine E. coli isolate-drug results in the NARMS database, the overall resistance rate was 21.60%.

The table below outlines the resistance rates for the primary drugs tested against E. coli:

Table 2: Antibiotic resistance rates in canine Escherichia coli (FDA NARMS, 2017–2021)

Antibiotic	Drug Class / Generation	Tests (N)	Resistant Count	Resistance %	Clinical Relevance
Ampicillin	Penicillin	7,061	2,402	34.02%	Simple penicillin; primary choice for uncomplicated UTIs historically.
Cefpodoxime	Cephalosporin (3rd Gen)	6,993	1,236	17.67%	Third-generation cephalosporin; resistance suggests ESBL production.
Enrofloxacin	Fluoroquinolone (2nd Gen)	7,154	1,121	15.67%	First-line choice for pyelonephritis and complex Gram-negative UTIs.
Gentamicin	Aminoglycoside	7,010	371	5.29%	Highly effective systemic Gram-negative option; requires renal monitoring.
Tetracycline	Tetracycline	6,686	1,044	15.61%	Muted resistance compared to Gram-positive cocci.

Key takeaways from the E. coli data

1. The ampicillin decline (34.02% resistance)

Ampicillin (and its oral counterpart, amoxicillin) has long been the classic choice for canine cystitis (bladder infections). With a 34.02% resistance rate, one-third of clinical E. coli infections will fail ampicillin therapy. This has led the International Society for Companion Animal Infectious Diseases (ISCAID) to favor amoxicillin primarily for uncomplicated sporadic UTIs, but with a strong recommendation to culture if clinical signs do not resolve rapidly.

2. The Gram-negative fluoroquinolone window (Enrofloxacin at 15.67%)

Unlike staphylococcus, E. coli retains a relatively high susceptibility to fluoroquinolones, with enrofloxacin resistance at 15.67%. While still a concern, this makes fluoroquinolones a viable option for upper urinary tract infections (like pyelonephritis) where deep tissue penetration is required, provided susceptibility is confirmed.

3. The doxycycline / tetracycline anomaly (Tetracycline at 15.61%)

Veterinary professionals will note that doxycycline is often reported as highly resistant for E. coli in clinical settings. In our NARMS analysis, doxycycline returned a 99.61% resistance rate (6,641 resistant out of 6,667 interpretable tests).

Clinically, this is considered a breakpoint or methodology artifact. E. coli possesses intrinsic resistance mechanisms (such as efflux pumps) that make tetracyclines, particularly doxycycline, highly ineffective in vivo, even if some class-level tetracycline tests suggest susceptibility. Doxycycline should never be used to treat an E. coli infection, particularly a UTI, as the drug does not achieve therapeutic concentrations in the urine.

Yearly trends: Is resistance growing exponentially?

A common narrative in veterinary medicine is that resistance is skyrocketing year over year. However, our longitudinal analysis of the NARMS dog-pathogen dataset from 2017 through 2021 reveals a more nuanced picture.

By grouping all dog isolate-drug susceptibility tests (298,658 tests with valid Susceptible/Resistant/Intermediate calls), we computed the overall resistance percentage for each calendar year:

Table 3: Year-over-year overall resistance rate in dog pathogen surveillance (FDA NARMS, 2017–2021)

Year	Total Interpretive Tests (N)	Resistant Interpretations	Resistance Percentage
2017	23,646	5,099	21.56%
2018	47,089	11,406	24.22%
2019	72,661	18,655	25.67%
2020	75,778	18,523	24.44%
2021	79,484	19,790	24.90%

Source: Computed by VetMedGuide from FDA NARMS companion-animal pathogen surveillance, 2017–2021 (interpretable susceptibility results).

Interpretation of the trend

Rather than an exponential rise, the data shows that overall resistance in canine diagnostic submissions rose from 21.56% in 2017 and has plateaued between 24.4% and 25.7% from 2019 through 2021.

While this plateau is somewhat reassuring—suggesting that veterinary education and antimicrobial stewardship programs are having a stabilizing effect—it is critical to recognize that this stability represents a very high baseline. One in four antibiotic choices made in clinical cases where a culture is performed will result in a treatment failure if selected empirically.

US surveillance vs. global data: The German laboratory study

How does US dog surveillance compare to other developed nations? A major peer-reviewed study published in Antibiotics (MDPI) in 2024 analyzed 175,171 bacterial test results collected from veterinary practices across Germany between 2019 and 2021 — roughly one-third of the country's registered clinics.

The German study provides an excellent comparison of pathogen isolation and resistance:

Prevalence of S. pseudintermedius: In Germany, S. pseudintermedius was isolated from 25.6% of all submitted clinical samples (and from 35.0% of canine samples), confirming its role as the dominant canine pyoderma pathogen globally.
MRSP Rates: The German study found methicillin resistance in 7.5% of all S. pseudintermedius isolates overall (7.1% in dogs and 16.1% in cats).

Why the difference?

The German MRSP rate of 7.1% in dogs appears much lower than the US NARMS oxacillin resistance rate of 34.28%. This difference is primarily due to denominator design:

The German study calculated prevalence across all submitted veterinary samples from primary-care clinics.
The US NARMS dataset represents diagnostic isolates submitted to academic and reference laboratories, which are heavily skewed toward chronic, refractory, and tertiary referral cases that have failed initial treatments.

This head-to-head comparison underlines the importance of context. If you are treating a first-time, simple skin infection, your dog's risk of MRSP is closer to the German single-digit baseline. But if you are managing a chronic, recurrent skin condition that has been treated with multiple rounds of cephalexin or Simplicef, the probability that you are dealing with a resistant MRSP strain climbs toward the 34.28% NARMS surveillance threshold.

What a "Resistant" culture result means in practice

If your dog's culture report lists "Resistant" next to every common oral antibiotic, it is natural to worry. However, understanding how to read these reports can demystify the process.

How to interpret a culture and susceptibility (C&S) report

A C&S report contains two main components:

Pathogen Identification: The laboratory isolates and grows the bacteria to identify the genus and species (e.g., Staphylococcus pseudintermedius).
Susceptibility Panel: The bacteria are exposed to various concentrations of different antibiotics. The laboratory determines the Minimum Inhibitory Concentration (MIC)—the lowest concentration of the drug that prevents visible bacterial growth.

The laboratory then compares the MIC to established clinical breakpoints set by the Clinical and Laboratory Standards Institute (CLSI). Based on these breakpoints, the drug is categorized as:

S (Susceptible): The infection can likely be treated with the standard dose of this antibiotic.
I (Intermediate): The drug may work if given at a higher dose or if it concentrates naturally at the site of infection (such as the urine).
R (Resistant): The drug is highly unlikely to succeed, even at maximum safe doses.

Empiric failure: The diagnostic pivot

If your dog's infection is resistant to first-line agents, your veterinarian will shift from empiric therapy to targeted therapy. This might involve:

Topical Therapy: The clinical secret to managing MRSP is that topical antiseptics (like chlorhexidine or benzoyl peroxide shampoos, sprays, and creams) bypass systemic resistance. A bacterium that survives a therapeutic oral cephalosporin cannot survive direct exposure to a 2% to 4% chlorhexidine wash.
Non-Traditional systemics: Reaching for tier-two systemic drugs like chloramphenicol, minocycline, or clindamycin/rifampin combinations, but only where supported by the susceptibility panel.
Addressing the Primary Driver: Most recurrent skin infections in dogs are secondary to an underlying allergy. Unless the allergy is managed (using drugs like Apoquel, Cytopoint, or immunotherapy), the skin barrier will remain compromised, and the infection will recur, driving further resistance.

For dogs experiencing recurrent skin flare-ups, read our guide on canine atopic dermatitis workup and when to transition from antibiotics to allergy management. For ear-specific infections, see our article on dog ear cytology to understand when a culture is indicated over standard topical treatments.

Zoonotic risk: Can resistant infections spread to humans?

One of the first questions owners ask when their dog is diagnosed with MRSP is: "Can my family catch this?"

The short answer

Yes, but the risk of active infection in healthy people is very low.

S. pseudintermedius is highly adapted to live on canine skin, which has a different pH and microclimate than human skin. While humans can become transiently colonized with MRSP (meaning the bacteria can temporarily rest on the skin or in the nose after petting an infected dog), it rarely causes active clinical disease (like abscesses or cellulitis) in healthy individuals.

Risk groups

The risk of active zoonotic MRSP infection increases for individuals who are:

Immunocompromised (due to chemotherapy, organ transplant, or active disease)
Very young or very old
Recovering from recent surgical wounds or skin breaches

Household infection control protocols

If your dog has a confirmed MRSP or resistant E. coli infection, follow these simple hygiene rules to protect your household:

Wash hands immediately with soap and water after petting, grooming, or administering medication to the infected dog.
Wear disposable gloves when cleaning wounds, applying topical creams, or handling infected ears.
Use a chlorhexidine-based wash or soap to clean any skin areas that come into contact with the dog's saliva or wound discharge.
Restrict the dog's access to human beds, pillows, and furniture during active treatment.
Wash pet bedding frequently in hot water with detergent and dry on high heat.
Clean bowls, toys, and grooming tools separately from human utensils using hot, soapy water.

When to seek a veterinary dermatology referral

Managing a resistant bacterial skin infection can be exhausting and expensive. If you are on your third or fourth course of antibiotics, or if your dog's skin remains red, itchy, and crusty despite targeted drugs, it is time to consider a board-certified veterinary dermatologist.

Referral triggers

You should request a referral to a veterinary dermatologist if your case meets any of the following criteria:

Confirmed MRSP pyoderma that does not show significant improvement within 14 days of starting a susceptibility-guided treatment.
Deep pyoderma (involving draining tracts, nodules, or severe swelling) where systemic therapy carries risk of organ toxicity.
More than three skin infections in a 12-month period, indicating that the underlying cause (allergy, endocrine disease, follicular dysplasia) has not been successfully identified.
The culture shows resistance to all oral veterinary antibiotics, leaving only high-risk human drugs (like linezolid or vancomycin) or strict topical protocols as options.

A veterinary dermatologist can design a comprehensive diagnostic workup to identify the root cause of the skin barrier compromise, implement specialized topical therapies, and help you break the cycle of recurrent antibiotic use.

FAQs

Is MRSP more dangerous than a normal staph infection in dogs?

No. MRSP is not inherently more aggressive, invasive, or toxic than susceptible S. pseudintermedius. It does not produce worse tissue damage on its own. The "danger" of MRSP lies entirely in the fact that it is more difficult to treat, meaning infections can persist longer, progress due to ineffective treatments, and require more expensive or potentially toxic drugs.

Your veterinarian recommended a culture because your dog has signs of a deep, recurrent, or atypical infection. Prescribing another empiric antibiotic without knowing if the bacteria are susceptible carries a high risk of treatment failure, wasted expense, and further selection for multidrug-resistant strains. Culturing allows the clinician to "target the enemy" with the narrowest, safest, and most effective drug possible.

Can resistant infections in dogs be prevented?

Yes. Prevention centers on two main principles:

Rational Antibiotic Use: Only use systemic antibiotics when absolutely necessary. Avoid short, incomplete courses, and never use leftovers from a previous prescription.
Skin Barrier Maintenance: Manage underlying allergies (atopic dermatitis, food allergy) aggressively to prevent the scratching and self-trauma that breach the skin barrier and allow opportunistic staph to take hold. Use regular topical antiseptic baths (such as chlorhexidine shampoos) as a preventative measure to keep bacterial populations low.

Sources

FDA Center for Veterinary Medicine (CVM): National Antimicrobial Resistance Monitoring System (NARMS) Integrated Reports and Summaries.
MDPI Antibiotics Study (2024): Prevalence and Resistance Patterns of Methicillin-Resistant Staphylococcus pseudintermedius (MRSP) in Canine and Feline Clinical Samples in Germany.
PMC Review (NIH): Methicillin-resistant Staphylococcus pseudintermedius: An Update on Clinical Management and Public Health Concerns.
Today's Veterinary Practice: Methicillin-Resistant Staphylococcal Infections in Dogs: Clinical Developments and Management.
Companion Animal Parasite Council (CAPC): Veterinary Infectious Disease Guidelines and Antimicrobial Use.

Antibiotic Resistance in Dogs: NARMS Data on MRSP and Resistant E. coli